Lineage director granted 125,000 stock options

Lineage Cell Therapeutics director Dipti Amin received a stock option grant covering 125,000 common shares.

Rhea-AI Filing Summary

Lineage Cell Therapeutics director Dipti Amin received a stock option grant covering 125,000 common shares. The option has an exercise price of $1.30 per share and expires on July 1, 2036. It will vest and become exercisable on the earlier of July 1, 2027 and the date of the company’s next annual shareholder meeting, subject to Amin’s continuous service. Following this grant, Amin holds options for 125,000 shares directly.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Amin Dipti

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 contracts (Direct)

Footnotes (1)

1. F1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

Key Figures

Option grant size: 125,000 options Exercise price: $1.30 per share Underlying shares: 125,000 shares +3 more

6 metrics

Option grant size 125,000 options Stock Option (Right to Buy) granted to director

Exercise price $1.30 per share Fixed price to buy Lineage common shares

Underlying shares 125,000 shares Common shares subject to the option

Post-grant holdings (options) 125,000 options Total derivative holdings following transaction

Vesting date trigger Earlier of July 1, 2027 or next annual meeting Subject to continuous service condition

Expiration date July 1, 2036 Last date to exercise the options

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.3000" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"Will vest and become exercisable on the earlier of July 1, 2027..."

expiration date financial

"expiration_date: "2036-07-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Shares""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lineage Cell Therapeutics (LCTX) director Dipti Amin receive in this Form 4?

Director Dipti Amin received a stock option grant for 125,000 common shares. The option is a compensation-related award, not an open-market purchase, and gives the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Dipti Amin’s stock options in LCTX?

The stock options have an exercise price of $1.30 per share. This is the fixed price at which Amin can buy Lineage Cell Therapeutics common shares once the options vest and become exercisable, regardless of the market price at that time.

When do Dipti Amin’s Lineage Cell Therapeutics options vest and become exercisable?

The options vest on the earlier of July 1, 2027 and the date of Lineage Cell Therapeutics’ next annual shareholder meeting. Vesting is also conditioned on Amin’s continuous service with the company through the applicable vesting date.

How many Lineage Cell Therapeutics shares are covered by Amin’s new option award?

The award covers 125,000 underlying common shares of Lineage Cell Therapeutics. Once vested and exercised at the $1.30 exercise price, each option can be converted into one common share, subject to the terms and expiration date of the grant.

What is the expiration date of Dipti Amin’s LCTX stock option grant?

The stock option grant expires on July 1, 2036. After this expiration date, any unexercised portion of the 125,000 options will lapse, and Amin will no longer have the right to purchase those shares at the stated exercise price.

Is Dipti Amin’s transaction in LCTX shares a market buy or sell?

The transaction is a grant of stock options, not a market buy or sell. It is reported with transaction code “A” as a grant, award, or other acquisition of derivative securities, issued as part of Amin’s compensation as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Amin Dipti

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.3	07/01/2026		A		125,000		(1)	07/01/2036	Common Shares	125,000	$0.00	125,000	D

Explanation of Responses:

1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

	/s/ Alexandra Hernandez, as Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)